All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb and Incyte. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View MPN content recommended for you
Ruxolitinib for the treatment of MF in clinical routine: Initial results from a phase IV study
Results from the phase IV non-interventional JAKoMo trial (NCT05044026) evaluating real-world ruxolitinib treatment outcomes in 943 patients with myelofibrosis (MF) (Arm A, ruxolitinib-naïve patients, n = 479; Arm B, ruxolitinib-experienced patients, n = 464) were published by Koschmieder et al. in the European Journal of Haematology.
Key data
- Ruxolitinib-naïve patients showed rapid (≤6 months), sustained improvements in spleen length (mean decrease from 19.0 cm to 16.89 cm at 12 months), constitutional symptoms, and quality of life (QoL) measures (~17% increase in the proportion of patients experiencing normal German QoL during follow-up in both arms).
- Adverse events (AEs) were less frequent than in registrational trials, with lower rates of anemia (24% vs 32%), reduced hemoglobin (7% vs 12%), and thrombocytopenia (12% vs 29%) in ruxolitinib-experienced vs -naïve patients.
- OS at 36 months (75%) was comparable to phase III COMFORT trial data.
Key learning
Real-world ruxolitinib treatment demonstrates significant and sustained clinical benefits for patients with MF, with maximum responses achieved within 6 months, supporting more conservative dosing strategies that maintain efficacy while potentially reducing AEs compared with clinical trial protocols.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
If you use erythropoiesis-stimulating agents (ESA) in the management of myelofibrosis, do you primarily base your use of ESA on patients’ erythropoietin (EPO) levels?
